Investing.com - Financial Markets Worldwide

Krystal Biotech stock hits 52-week high at 213.09 USD

Published 21/11/2025, 19:52
Krystal Biotech stock hits 52-week high at 213.09 USD
KRYS
-0.32%

Krystal Biotech Inc (KRYS) stock reached a notable milestone, hitting a 52-week high of 213.09 USD. This surge reflects a positive momentum for the company, marking a significant point in its trading history over the past year. InvestingPro data shows the biotech firm has delivered impressive returns of 61.21% over the past six months and 30.36% year-to-date, significantly outperforming broader market indices. Over the last 12 months, Krystal Biotech has experienced a commendable 1-year change of 11.31%, indicating steady growth and investor confidence in the company’s prospects. The biotech firm’s recent performance highlights its resilience and potential within the market. With exceptional gross profit margins of 94.26% and revenue growth of 54.51%, KRYS demonstrates strong operational efficiency. According to InvestingPro, the company maintains an "EXCELLENT" financial health rating and appears slightly undervalued based on Fair Value estimates. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for KRYS and 1,400+ other US equities through the InvestingPro platform.

In other recent news, Krystal Biotech Inc. reported a notable earnings beat for the third quarter of 2025. The company achieved earnings per share of $2.66, significantly surpassing the forecasted $1.09. This represents a surprise increase of 144.04%. Despite the impressive financial performance, the company’s stock price experienced a decline, although this was influenced by broader market trends and not company-specific issues. There were no reports of mergers or acquisitions involving Krystal Biotech during this period. Analyst actions regarding the company’s stock were not highlighted in recent developments. Additionally, no other major company news was reported. These updates reflect the latest developments concerning Krystal Biotech Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.